METHOD FOR PREDICTION OF DEVELOPING METASTASES IN UTERINE CANCER PATIENTS BASED ON ANALYSIS OF MAGEA1, MAGEB2 AND PRAME1 GENE EXPRESSION Russian patent published in 2019 - IPC G01N33/574 C12Q1/6876 C12Q1/6806 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to molecular biology, oncology, and aims at predicting the development of metastases in uterine cancer patients. Total RNA is recovered from uterine tissue samples by guanidine-thioniate-phenol-chloroform extraction method. MAGEA1, MAGEB2 and PRAME1 genes are real-time amplified. Relative expression of the genetic loci is calculated with subsequent calculation of the relative expression coefficient K. Obtained values of K are compared with an interval of the prognostic expression coefficient. At values of K_MAGEA1<1.9±0.47, K_MAGEB2<1.0±0.54 and K_PRAME1<1.1±0.21 one predicts the course of the disease without metastases. At values of K_MAGEA1>3.9±0.87, K_MAGEB2>11.5±1.59 and K_PRAME1>3.8±0.98 shows development of metastases.

EFFECT: invention provides creating a new, easy-to-implement, inexpensive and more accurate method for prediction of developing metastases in patients diagnosed with uterine body cancer.

1 cl, 1 tbl, 2 ex